Current role and safety profile of aromatase inhibitors in early breast cancer. - Wikidata - awgldk - TriplyDB

Current role and safety profile of aromatase inhibitors in early breast cancer.

Current role and safety profile of aromatase inhibitors in early breast cancer.

http://www.wikidata.org/entity/Q37931895

about

Fertility drugs, reproductive strategies and ovarian cancer risk.Validation of a rapid and sensitive LC-MS/MS method for determination of exemestane and its metabolites, 17β-hydroxyexemestane and 17β-hydroxyexemestane-17-O-β-D-glucuronide: application to human pharmacokinetics study.Novel aromatase inhibitors selection using induced fit docking and extra precision methods: Potential clinical use in ER-alpha-positive breast cancer.The effect and mechanism of tamoxifen-induced hepatocyte steatosis in vitro.Benzylmorpholine analogs as selective inhibitors of lung cytochrome P450 2A13 for the chemoprevention of lung cancer in tobacco users.Electroretinographic and optical coherence tomography findings in breast cancer patients using aromatase inhibitors.Comparison of Changes in the Lipid Profiles of Eastern Chinese Postmenopausal Women With Early-Stage Breast Cancer Treated With Different Aromatase Inhibitors: A Retrospective Study.Structure-activity relationships and docking studies of synthetic 2-arylindole derivatives determined with aromatase and quinone reductase 1.Musculoskeletal pain and health-related quality of life among breast cancer patients treated with aromatase inhibitors.Aromatase inhibitors and mood disturbances.

P2860

Q33608317-FCAC3F4E-98C4-421F-AE7A-195D07D10323 Q35203256-CE38302C-27FD-4488-A584-042C13748C1B Q37658821-3B32DA4F-A60A-4058-933C-C5FFC1F9486D Q37684018-1C7F417A-8092-4635-8D50-D17C080EB2B1 Q42970314-A2297987-29A9-44C7-9E4D-B4AFDDEAAE20 Q45029964-6EEF99F2-EFE5-45A9-8F22-5DFE0273E6ED Q47233921-0CA001E0-149A-401D-AB30-B647AD1B9A8D Q47387176-0F10574E-F046-4D09-B8C7-066E4E6FB4B2 Q48068071-9967250E-F702-4E24-ABF3-3F86EB7AE3F0 Q50951703-2E8948D8-5E72-4993-BEF5-AE9A4D2072A1

P2860

Current role and safety profile of aromatase inhibitors in early breast cancer.

http://www.wikidata.org/entity/Q37931895

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Current role and safety profile of aromatase inhibitors in early breast cancer.

@en

Current role and safety profile of aromatase inhibitors in early breast cancer.

@nl

type

label

Current role and safety profile of aromatase inhibitors in early breast cancer.

@en

Current role and safety profile of aromatase inhibitors in early breast cancer.

@nl

prefLabel

Current role and safety profile of aromatase inhibitors in early breast cancer.

@en

Current role and safety profile of aromatase inhibitors in early breast cancer.

@nl

P1433

Q37931895-0FA6F8BA-AF2A-4374-A11B-F1894A96B013

P1476

Q37931895-21414860-FD51-4762-A5C6-86A56948EC77

P2093

Q37931895-300EFD16-F655-4ED0-9A0F-219D775B6AE0

Q37931895-663A456E-09FD-4EC9-83D7-1672AE3A88B7

Q37931895-7246B799-2990-4EBC-8FB7-DBB739B02371

Q37931895-849636DD-0939-47CD-B32A-C1C562555015

Q37931895-861949DE-BBFA-462B-9FD6-2AA121775360

Q37931895-9365AC12-3808-41E2-BFC5-5A75D0DF484B

Q37931895-A3416925-E326-45FA-B1EF-3D75DD646B1D

Q37931895-FB10DF51-84F7-4A33-8F7B-8F448CA41DF1

P2860

Q37931895-10DF2A58-3E32-4799-9888-2B8F808986B4

Q37931895-20FB4FAA-285C-49E6-B26C-FA3F75028EDD

Q37931895-265607DA-5CE6-4833-9863-DC24242BE322

Q37931895-2964530B-3999-4BD6-BCC6-56D2CE58D36F

Q37931895-3E5CE57F-41B6-4FCB-8887-0CDFB24EEA01

Q37931895-406EFF50-EA93-4CD7-827A-6F7B81420AC5

Q37931895-412FE656-C8D3-41B4-A8FF-D54B03559E96

Q37931895-4183FAC4-01D3-46EA-AD2B-182B815B825F

Q37931895-524A79F2-4DF4-41D3-A9D6-E30F17814AD6

Q37931895-536CFBFA-77BF-4921-96C1-8AE929C0FEA6

P304

Q37931895-23CD4C12-7F83-4D08-8F94-48D1423CA9F7

P31

Q37931895-A07D3EFF-5E4E-43EE-9C2C-700161B90BC8

P356

Q37931895-80098BBB-601D-45BD-A0FE-B5BC34CB8DB2

P433

Q37931895-66947595-B04F-4C16-9F5B-56651EC6CB3B

P478

Q37931895-D460DDF6-71D2-43D9-9D3F-62F32C17DDA2

P577

Q37931895-501DD9BD-C071-4DF9-9B60-3DB8244EFDB3

P698

Q37931895-C739FA3E-E602-4152-A603-AB68827C40CE

P356

P1433

Expert Review of Anticancer Therapy

P1476

Current role and safety profile of aromatase inhibitors in early breast cancer.

@en

P2093

Federica Tomao

http://www.w3.org/2001/XMLSchema#string

Gianluca Cascialli

http://www.w3.org/2001/XMLSchema#string

Gianpaolo Spinelli

http://www.w3.org/2001/XMLSchema#string

Giovanni Codacci Pisanelli

http://www.w3.org/2001/XMLSchema#string

Luigi Frati

http://www.w3.org/2001/XMLSchema#string

Patrizia Vici

http://www.w3.org/2001/XMLSchema#string

Pierluigi Benedetti Panici

http://www.w3.org/2001/XMLSchema#string

Silverio Tomao

http://www.w3.org/2001/XMLSchema#string

P2860

Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.

Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen.

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial.

P304

1253-1263

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.11.96

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21916579

http://www.w3.org/2001/XMLSchema#string